DB ups Roche to 'buy' on positive oncology survey
BUZZ-DB ups Roche to 'buy' on positive oncology survey ** Deutsche Bank DBKGn.DE upgrades Swiss healthcare company Roche ROPC.S to "buy" from "hold" driven by positive physician feedback from a proprietary oncology survey
** DB notes that physician sentiment on breast cancer treatment giredestrant has leaned positive for some time with implications resonating in the near term
** Analysts at the bank admit being "late to a consensus trade" but argue they see little obvious reason for a better entry point into the stock anytime soon
** They add that immediate pipeline risks have diminished while modest expectations for fenebrutinib mean multiple sclerosis data offer limited concern
** Out of 24 analysts that cover the stock, 12 rate the it "strong buy" or "buy", 10 rate it "hold" and 2 rate it "strong sell" or "sell" - LSEG data
(Reporting by Maria Rugamer)
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey